두경부 편평상피암 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 치료법별, 투여 경로별, 최종 사용자별, 지역별 및 경쟁(2021-2031년)

The global market for Head and Neck Squamous Cell Carcinoma (HNSCC) is projected to expand significantly, rising from USD 2.49 Billion in 2025 to USD 4.09 Billion by 2031, demonstrating an 8.62% CAGR. HNSCC is defined as a malignant growth originating from the mucosal lining of the oral cavity, pharynx, and larynx. This market growth is primarily propelled by the ongoing presence of risk factors like tobacco use and excessive alcohol intake, coupled with a notable rise in Human Papillomavirus infections. Moreover, the worldwide aging population contributes to an increasing patient pool, demanding sophisticated therapeutic approaches. For instance, the American Cancer Society estimates approximately 59,660 new cases of oral cavity and pharynx cancer will be diagnosed in the U.S. in 2025.

However, despite these strong growth impetuses, the market encounters considerable obstacles, particularly the elevated costs of innovative immunotherapies and targeted drugs. Such financial impediments can significantly restrict patient access to effective treatments, especially in developing regions with limited healthcare resources. Additionally, the severe toxic effects linked with conventional chemoradiation regimens frequently complicate patient adherence and diminish their quality of life. This confluence of economic strains and clinical management challenges poses a major hurdle that could hinder the sector's overall expansion.

Market Driver

The primary force propelling market expansion is the increasing global incidence of Head and Neck Squamous Cell Carcinoma (HNSCC), driven by the ongoing prevalence of key risk factors like tobacco use, alcohol consumption, and Human Papillomavirus (HPV) infections. This growing disease burden necessitates an urgent need for enhanced diagnostic accuracy and broader therapeutic accessibility in both developed and emerging nations. With the rising number of patients, healthcare systems are compelled to dedicate more resources to oncology services, thereby directly enlarging the market for screening and treatment options. The National Institutes of Health's September 2025 'Global burden of head and neck cancer' report highlights this significant scale, noting that approximately 947,211 new cases of head and neck cancer were diagnosed worldwide in 2022, signifying a vast population requiring intervention.

A second significant driver is the swift progress in immunotherapy and targeted therapeutics, which are fundamentally transforming clinical results and increasing market valuation through the introduction of highly effective biological treatments. Pharmaceutical firms are heavily investing in new checkpoint inhibitors and combination therapies that offer superior survival rates compared to conventional chemoradiation. These innovations are substantiated by breakthrough findings from late-stage trials that are setting new benchmarks for care. For example, the American Society of Clinical Oncology's June 2025 'NIVOPOSTOP' trial revealed that adding nivolumab to chemoradiotherapy decreased disease recurrence risk by 24% in patients with locally advanced squamous cell carcinoma. Further underscoring this competitive advancement, Fierce Pharma reported in April 2025 that Merck's Keytruda, in the KEYNOTE-689 trial, reduced the risk of recurrence or death by 27% with perioperative pembrolizumab compared to standard treatment.

Market Challenge

A significant impediment to the growth of the Global Head and Neck Squamous Cell Carcinoma market is the elevated cost associated with novel immunotherapies and targeted drugs. Although these advanced treatment options demonstrate clinical effectiveness, their excessively high prices result in substantial financial strain for both patients and healthcare systems. This economic burden is particularly severe in developing nations that operate with restricted healthcare budgets, often lacking adequate reimbursement structures to cover costly oncological therapies. As a direct consequence, a considerable portion of the eligible patient demographic is unable to access optimal care, thereby diminishing the potential market size for these pharmaceutical innovations.

This financial obstacle generates a cascading effect that hinders wider market expansion. Frequently, high out-of-pocket expenses compel patients to postpone or decline crucial medical interventions, leading to decreased treatment adherence and reduced utilization of medications. A 2025 survey by the American Cancer Society Cancer Action Network highlighted this, indicating that 31% of adults were over a year behind on recommended cancer healthcare services, with more than half attributing this delay primarily to out-of-pocket costs. Such economic pressures not only restrict the adoption of sophisticated drugs but also complicate clinical management, ultimately impeding the sector's potential for revenue growth.

Market Trends

The integration of AI-driven radiomics is revolutionizing the clinical management of head and neck cancers by addressing the deficiencies of conventional imaging in identifying hidden metastases, thereby offering enhanced precision in diagnosis and prognosis. Sophisticated machine learning algorithms are now being applied to analyze intricate quantitative data from PET and CT scans, facilitating the accurate, non-invasive detection of lymph node involvement. This technological advancement allows for more tailored surgical and radiotherapeutic treatment plans, reducing unnecessary interventions while effectively targeting high-risk regions. A meta-analysis published in Neuroradiology in February 2025, titled 'Diagnostic accuracy of radiomics and artificial intelligence models,' reported that deep learning models achieved a pooled Area Under the Curve (AUC) of 92% for diagnosing lymph node metastasis via PET/CT imaging.

Concurrently, the rise of therapeutic cancer vaccines and oncolytic viral therapies signifies a crucial shift towards active immunization methods aimed at preventing disease recurrence in high-risk patients following surgery. In contrast to passive checkpoint inhibitors, these innovative treatments employ patient-specific neoantigens or viral vectors to prime the immune system to combat remaining tumor cells, potentially offering a curative option with a more favorable toxicity profile. This trend holds particular significance in the adjuvant setting, where maintaining remission is a vital unmet clinical requirement. As reported by Transgene in November 2024, in their 'Transgene and NEC Present New Data' press release, the TG4050 neoantigen vaccine demonstrated remarkable effectiveness, with all 16 treated patients remaining disease-free after a median follow-up period of 24.1 months.

Key Market Players

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• AstraZeneca PLC
• Eli Lilly and Company
• Novartis AG
• Sanofi S.A.
• Bayer AG
• GlaxoSmithKline plc

Report Scope

In this report, the Global Head and Neck Squamous Cell Carcinoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Head and Neck Squamous Cell Carcinoma Market, By Type

• Salivary Gland
• Oral and Oropharyngeal
• Nasal Cavity & Paranasal Sinuses
• Nasopharyngeal
• Laryngeal
• Hypo Pharyngeal

Head and Neck Squamous Cell Carcinoma Market, By Treatment

• Radiation
• Chemotherapy
• Immunotherapy

Head and Neck Squamous Cell Carcinoma Market, By Route of Administration

• Oral
• Intravenous
• Others

Head and Neck Squamous Cell Carcinoma Market, By End-user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Head and Neck Squamous Cell Carcinoma Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Head and Neck Squamous Cell Carcinoma Market.

Available Customizations:

Global Head and Neck Squamous Cell Carcinoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Head and Neck Squamous Cell Carcinoma Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Salivary Gland, Oral and Oropharyngeal, Nasal Cavity & Paranasal Sinuses, Nasopharyngeal, Laryngeal, Hypo Pharyngeal)
  • 5.2.2. By Treatment (Radiation, Chemotherapy, Immunotherapy)
  • 5.2.3. By Route of Administration (Oral, Intravenous, Others)
  • 5.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Head and Neck Squamous Cell Carcinoma Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By End-user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Head and Neck Squamous Cell Carcinoma Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End-user
  • 6.3.2. Canada Head and Neck Squamous Cell Carcinoma Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End-user
  • 6.3.3. Mexico Head and Neck Squamous Cell Carcinoma Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End-user

7. Europe Head and Neck Squamous Cell Carcinoma Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By End-user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End-user
  • 7.3.2. France Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End-user
  • 7.3.3. United Kingdom Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End-user
  • 7.3.4. Italy Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End-user
  • 7.3.5. Spain Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End-user

8. Asia Pacific Head and Neck Squamous Cell Carcinoma Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By End-user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End-user
  • 8.3.2. India Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End-user
  • 8.3.3. Japan Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End-user
  • 8.3.4. South Korea Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End-user
  • 8.3.5. Australia Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End-user

9. Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By End-user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Head and Neck Squamous Cell Carcinoma Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End-user
  • 9.3.2. UAE Head and Neck Squamous Cell Carcinoma Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End-user
  • 9.3.3. South Africa Head and Neck Squamous Cell Carcinoma Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End-user

10. South America Head and Neck Squamous Cell Carcinoma Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By End-user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Head and Neck Squamous Cell Carcinoma Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End-user
  • 10.3.2. Colombia Head and Neck Squamous Cell Carcinoma Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End-user
  • 10.3.3. Argentina Head and Neck Squamous Cell Carcinoma Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Head and Neck Squamous Cell Carcinoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Pfizer Inc.
• 15.5. AstraZeneca PLC
• 15.6. Eli Lilly and Company
• 15.7. Novartis AG
• 15.8. Sanofi S.A.
• 15.9. Bayer AG
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer